Renal function, nephrogenic systemic fibrosis and other adverse reactions associated with gadolinium-based contrast media

被引:10
|
作者
Canga, Ana [1 ]
Kislikova, Maria [2 ]
Martinez-Galvez, Maria [3 ]
Arias, Mercedes [4 ]
Fraga-Rivas, Patricia [5 ]
Poyatos, Cecilio [6 ]
de Francisco, Angel L. M. [2 ]
机构
[1] Hosp Univ Marques de Valdecilla, Serv Radiodiagnost, Santander 39008, Spain
[2] Hosp Univ Marques de Valdecilla, Serv Nefrol, Santander 39008, Spain
[3] Hosp Jose Maria Morales Meseguer, Serv Radiodiagnost, Murcia, Spain
[4] Complejo Hosp Univ Vigo, Empresa Publ Serv Sanitarios, Unidad Diagnost Imagen Galaria, Pontevedra, Spain
[5] Hosp del Henares, Serv Radiodiagnost, Unidad Cent Radiodiagnost, Madrid, Spain
[6] Hosp Univ Dr Peset, Serv Radiodiagnost, Valencia, Spain
来源
NEFROLOGIA | 2014年 / 34卷 / 04期
关键词
Nephrogenic systemic fibrosis; Gadolinium; Magnetic resonance; Adverse reactions; CLINICAL SAFETY; DERMOPATHY; AGENTS; INVOLVEMENT; EXPERIENCE; DEPOSITION; DISORDER; PATIENT; RISK;
D O I
10.3265/Nefrologia.pre2014.Apr.12375
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Nephrogenic systemic fibrosis is a fibrosing disorder that affects patients with impaired renal function and is associated with the administration of gadolinium-based contrast media used in MRI. Despite being in a group of drugs that were considered safe, report about this potentially serious adverse reaction was a turning point in the administration guidelines of these contrast media. There has been an attempt to establish safety parameters to identify patients with risk factors of renal failure. The close pharmacovigilance and strict observation of current regulations, with special attention being paid to the value of glomerular filtration, have reduced the published cases involving the use of gadolinium-based contrast media. In a meeting between radiologists and nephrologists we reviewed the most relevant aspects currently and recommendations for its prevention.
引用
收藏
页码:428 / 438
页数:11
相关论文
共 50 条
  • [1] Nephrogenic systemic fibrosis and gadolinium-based contrast media
    Andrejak, Michel
    Thuillier, Delphine
    Lok, Catherine
    Gras-Champel, Valerie
    THERAPIE, 2007, 62 (02): : 169 - 172
  • [2] Nephrogenic systemic fibrosis (NSF) and gadolinium-based contrast media
    Ngoya, P. S.
    Vawda, Z.
    Lotz, J. W.
    SA JOURNAL OF RADIOLOGY, 2013, 17 (03): : 106 - 107
  • [3] Gadolinium-based contrast media and the development of nephrogenic systemic fibrosis in patients with renal insufficiency
    Chewning, Rush H.
    Murphy, Kieran J.
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2007, 18 (03) : 331 - 333
  • [4] ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis
    Thomsen, Henrik S.
    EUROPEAN RADIOLOGY, 2007, 17 (10) : 2692 - 2696
  • [5] ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis
    Henrik S. Thomsen
    European Radiology, 2007, 17 : 2692 - 2696
  • [6] Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Agents
    Abu-Alfa, Ali K.
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2011, 18 (03) : 188 - 198
  • [7] Nephrogenic systemic fibrosis as an adverse drug reaction of gadolinium-based contrast media for magnetic resonance imaging
    Giersig, C.
    RADIOLOGE, 2007, 47 (09): : 794 - 799
  • [8] Nephrogenic systemic fibrosis: UK survey of the use of gadolinium-based contrast media
    Rees, O.
    Agarwal, S. K.
    CLINICAL RADIOLOGY, 2010, 65 (08) : 636 - 641
  • [9] Gadolinium-based Contrast Agents and Nephrogenic Systemic Fibrosis Response
    Semelka, Richard C.
    Altun, Ersan
    Wertman, Rebecca
    Martin, Diego R.
    Leyendecker, John R.
    O'Malley, Ryan B.
    Parsons, Daniel J.
    Fuller, Edwin R., III
    Mitchell, Donald G.
    RADIOLOGY, 2009, 250 (03) : 959 - U457
  • [10] Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents
    Penfield, Jeffrey G.
    PEDIATRIC NEPHROLOGY, 2008, 23 (12) : 2121 - 2129